[go: up one dir, main page]

PE20080923A1 - Forma cristalina polimorfica qalfa de maleato de (r)-5-[2-(5,6-dietil-indan-2-il-amino)-1-hidroxi-etil]-8-hidroxi-1h-quinolin-2-ona - Google Patents

Forma cristalina polimorfica qalfa de maleato de (r)-5-[2-(5,6-dietil-indan-2-il-amino)-1-hidroxi-etil]-8-hidroxi-1h-quinolin-2-ona

Info

Publication number
PE20080923A1
PE20080923A1 PE2007001166A PE2007001166A PE20080923A1 PE 20080923 A1 PE20080923 A1 PE 20080923A1 PE 2007001166 A PE2007001166 A PE 2007001166A PE 2007001166 A PE2007001166 A PE 2007001166A PE 20080923 A1 PE20080923 A1 PE 20080923A1
Authority
PE
Peru
Prior art keywords
hydroxy
indan
ona
diethyl
ethyl
Prior art date
Application number
PE2007001166A
Other languages
English (en)
Inventor
Olivier Lohse
Guido Jordine
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080923(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080923A1 publication Critical patent/PE20080923A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A LA FORMA CRISTALINA POLIMORFICA QALFA DEL COMPUESTO MALEATO DE (R)-5-[2-(5,6-DIETIL-INDAN-2-IL-AMINO)-1-HIDROXI-ETIL]-8-HIDROXI-1H-QUINOLIN-2-ONA QUE TIENE UN PATRON DE DIFRACCION DE RAYOS X EXPRESADO EN GRADOS 2O DE 5.3, 10.1, 12.7, 16.4, 20.0, 25.8, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION DE DICHO COMPUESTO QUE COMPRENDE CRISTALIZAR EL MALEATO DE (R)-5-[2-(5,6-DIETIL-INDAN-2-IL-AMINO)-1-HIDROXI-ETIL]-8-HIDROXI-1H-QUINOLIN-2-ONA EN UNA SOLUCION DE ETANOL DESNATURALIZADO QUE CONTIENE 90% DE ETANOL, 5% DE AGUA Y 5% DE ISOPROPANOL. DICHO COMPUESTO ES AGONISTA DEL ADRENOCEPTOR BETA-2 SIENDO UTIL COMO BRONCODILATADOR
PE2007001166A 2006-08-31 2007-08-28 Forma cristalina polimorfica qalfa de maleato de (r)-5-[2-(5,6-dietil-indan-2-il-amino)-1-hidroxi-etil]-8-hidroxi-1h-quinolin-2-ona PE20080923A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119895A EP1914227A1 (en) 2006-08-31 2006-08-31 Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist

Publications (1)

Publication Number Publication Date
PE20080923A1 true PE20080923A1 (es) 2008-07-11

Family

ID=37714644

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001166A PE20080923A1 (es) 2006-08-31 2007-08-28 Forma cristalina polimorfica qalfa de maleato de (r)-5-[2-(5,6-dietil-indan-2-il-amino)-1-hidroxi-etil]-8-hidroxi-1h-quinolin-2-ona

Country Status (21)

Country Link
US (1) US20100010039A1 (es)
EP (2) EP1914227A1 (es)
JP (1) JP2010501631A (es)
KR (1) KR20090049615A (es)
CN (1) CN101511794A (es)
AR (1) AR063698A1 (es)
AU (1) AU2007291270A1 (es)
BR (1) BRPI0716383A2 (es)
CA (1) CA2659144A1 (es)
CL (1) CL2007002525A1 (es)
GT (1) GT200900037A (es)
IL (1) IL196805A0 (es)
MA (1) MA30763B1 (es)
MX (1) MX2009002301A (es)
NO (1) NO20091234L (es)
PE (1) PE20080923A1 (es)
RU (1) RU2009111389A (es)
TN (1) TN2009000056A1 (es)
TW (1) TW200817333A (es)
WO (1) WO2008025816A1 (es)
ZA (1) ZA200900264B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010299393A1 (en) * 2009-09-25 2012-04-05 Kyorin Pharmaceutical Co., Ltd. Maleic acid salt and crystal thereof
WO2014154841A1 (en) 2013-03-27 2014-10-02 Laboratorios Lesvi, S.L. Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one
CN103830195A (zh) * 2014-03-11 2014-06-04 熊妲妮 一种茚达特罗片及其制备方法
CN103830193A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗片制剂及其制备方法
ES2747905T3 (es) 2015-09-29 2020-03-12 Inke Sa Solvato mixto de L-tartrato de (R)-5-[2-(5,6-dietilindan-2-ilamino)-1-hidroxietil]-8-hidroxi-1H-quinolin-2-ona

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2010501631A (ja) 2010-01-21
TN2009000056A1 (en) 2010-08-19
CA2659144A1 (en) 2008-03-06
TW200817333A (en) 2008-04-16
EP2066639A1 (en) 2009-06-10
AR063698A1 (es) 2009-02-11
US20100010039A1 (en) 2010-01-14
GT200900037A (es) 2010-03-11
MA30763B1 (fr) 2009-10-01
CL2007002525A1 (es) 2008-07-11
NO20091234L (no) 2009-03-30
CN101511794A (zh) 2009-08-19
ZA200900264B (en) 2010-05-26
EP1914227A1 (en) 2008-04-23
KR20090049615A (ko) 2009-05-18
IL196805A0 (en) 2009-11-18
RU2009111389A (ru) 2010-10-10
WO2008025816A1 (en) 2008-03-06
MX2009002301A (es) 2009-03-20
BRPI0716383A2 (pt) 2013-09-24
AU2007291270A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
PE20061142A1 (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
NZ600207A (en) Substituted 4-aminocyclohexane derivatives
EA200971104A1 (ru) Производные бензимидазола
UY30051A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
EP2178869A4 (en) INDOL COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
TW200510277A (en) Crystalline form of β2-adrenergic receptor agonist
CO6290644A2 (es) Antagonista del receptor opioide selectivo kappa.
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
CO6140054A2 (es) Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico
PE20080923A1 (es) Forma cristalina polimorfica qalfa de maleato de (r)-5-[2-(5,6-dietil-indan-2-il-amino)-1-hidroxi-etil]-8-hidroxi-1h-quinolin-2-ona
EP3091019A3 (en) Purine derivatives useful as hsp90 inhibitors
WO2011008312A3 (en) Indole and indoline derivatives and methods of use thereof
AR040021A1 (es) (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion
PE20061014A1 (es) Clorhidrato de lercanidipina amorfo
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos
EA200701676A1 (ru) Производные дигидроимидазотиазола
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
AR060733A1 (es) Proceso para la precipitacion y el aislamiento de compuestos de 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen los mismos
WO2010019203A8 (en) Antifungal agents
MX2010004235A (es) Piperidinas tri-sustituidas.
BRPI0515193A (pt) novos polimorfos de azabiciclohexano

Legal Events

Date Code Title Description
FC Refusal